MoonLake Immunotherapeutics
MLTX
109 hedge funds and large institutions have $3.14B invested in MoonLake Immunotherapeutics in 2024 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 53 increasing their positions, 22 reducing their positions, and 19 closing their positions.
141% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 22
21% more call options, than puts
Call options by funds: $6.04M | Put options by funds: $5M
17% more capital invested
Capital invested by funds: $2.67B → $3.14B (+$465M)
2.29% more ownership
Funds ownership: 96.73% → 99.02% (+2.3%)
2% less funds holding
Funds holding: 111 → 109 (-2)
11% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 19
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$61.2M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$43.6M |
| 3 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$30.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.6M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
+$16.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$61.9M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$33M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$10.5M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$8.96M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.46M |
MLTX Hedge Fund Activity: Q3 2024 in Review
109 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in MoonLake Immunotherapeutics (MLTX) for Q3 2024, worth a combined $3.14B — up 17% from $2.67B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of MLTX and 17 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 53 added.
The largest buyer was Fidelity Investments, adding an estimated $61.2M. The largest seller was Adage Capital Partners, cutting an estimated $61.9M.
- 109 institutional investors held MoonLake Immunotherapeutics (MLTX) as of Q3 2024, down from 111 in Q2 2024.
- Funds reported $3.14B of MoonLake Immunotherapeutics stock for Q3 2024, up 17% quarter-over-quarter.
- 17 funds opened new MoonLake Immunotherapeutics positions in Q3 2024 and 19 closed out, a net change of -2 holders.
- The largest MoonLake Immunotherapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $61.2M added.
- The largest MoonLake Immunotherapeutics seller in Q3 2024 was Adage Capital Partners, an estimated $61.9M sold.
Based on aggregated 13F filings for Q3 2024.